MSD Contact Information Legal Terms MSD Jobs
MESO SCALE DISCOVERY
MESO SCALE DISCOVERY
Catalog
MULTI-ARRAY Detection Technology
Products
Literature & Publications
Applications Literature
Brochures
Customer Presentations
MSD Assay Product Inserts
Technical & Application Notes
MSD Publication References
Our Company
Purchase MSD Assays
Shows & Events We Attend
 



Publications

Comparison of Multiplex Immunoassay Platforms.

Fu, Q., Zhu, J., Van Eyk, J.E.

Journal Clinical Chemistry. Year 2010
Species Human Volume 56 (2)
IL-1β, IL-10, IL-12 p70, IL-2, IL-6 Page # 314-318
Matrix Tested Serum Cytokines & Chemokines

Abstract

BACKGROUND: Candidate biomarkers discovered with high-throughput proteomic techniques (along with many biomarkers reported in the literature) must be rigorously validated. The simultaneous quantitative assessment of multiple potential biomarkers across large cohorts presents a major challenge to the field. Multiplex immunoassays represent a promising solution, with the potential to provide quantitative data via parallel analyses. These assays also require substantially less sample and reagents than the traditional ELISA (which is further limited by its ability to measure only a single antigen). We have measured the reproducibility, reliability, robustness, accuracy, and throughput of commercially available multiplex immunoassays to ascertain their suitability for serum biomarker analysis and validation.

METHODS: Assay platforms MULTI-ARRAY (Meso Scale Discovery), Bio-Plex (Bio-Rad Laboratories), A(2) (Beckman Coulter), FAST Quant (Whatman Schleicher & Schuell BioScience), and FlowCytomix (Bender MedSystems) were selected as representative examples of technologies currently used for high-throughput immunoanalysis. All assays were performed according to protocols specified by the manufacturers and with the reagents (diluents, calibrators, blocking reagents, and detecting-antibody mixtures) included with their kits.

RESULTS: The quantifiable interval determined for each assay and antigen was based on precision (CV < 25%) and percentage recovery (measured concentration within 20% of the actual concentration). The MULTI-ARRAY and Bio-Plex assays had the best performance with the lowest limits of detection, and the MULTI-ARRAY system had the most linear signal output over the widest concentration range (10(5) to 10(6)). Cytokine concentrations in unspiked and cytokine-spiked serum samples from healthy individuals were further investigated with the MULTI-ARRAY and Bio-Plex assays.

CONCLUSIONS: The MULTI-ARRAY and Bio-Plex multiplex immunoassay systems are the most suitable for biomarker analysis or quantification.

View Publication


Related Products
Human Demonstration 10-Plex Base Kit
Human Demonstration 10-Plex Tissue Culture Kit
Human Demonstration 4-Plex Base Kit
Human Demonstration 4-Plex Tissue Culture Kit
Human Demonstration 7-Plex Base Kit
Human Demonstration 7-Plex Tissue Culture Kit
Human ProInflammatory 7-Plex Base Kit
Human ProInflammatory 7-Plex Tissue Culture Kit
Human ProInflammatory 7-Plex Ultra-Sensitive Kit
Human ProInflammatory 9-Plex Base Kit

view more

Suggest a Reference


Speak with a Scientist



CAREERS     |     CONTACT US     |     LEGAL     |     PRIVACY
Feedback Form
Feedback Analytics